Zymeworks Inc. Stock News

Zymeworks is gaining momentum as Ziihera shows strong Phase III data in HER2+ gastroesophageal adenocarcinoma, supporting growth and de-risking the investment. ZYME's royalty-based business model with partners like Jazz and BeOne enables pipeline focus while targeting blockbuster potential, with peak sales estimates exceeding $2B for Ziihera. Risks remain, including regulatory uncertainties and...

This article revisits Zymeworks Inc. following significant new trial data released this week. This triggered a 30% rally in ZYME stock on Monday, even as most of any future revenues will accrue to partners Jazz Pharmaceuticals and BeOne. Zymeworks does have a solid balance sheet, several additional partnerships with major drug concerns, and multiple other ADCs in development.

Zymeworks Inc. ( ZYME ) Shareholder/Analyst Call November 18, 2025 8:30 AM EST Company Participants Shrinal Inamdar - Director of Investor Relations Kenneth Galbraith - Chairman of the Board, CEO & President Conference Call Participants Seung Won Paik - LifeSci Capital, LLC, Research Division Andrew Berens - Leerink Partners LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, In...

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer.

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced a novel strategic initiative focused on optimizing future cash flows from Ziihera® (zanidatamab-hrii), other licensed products and ot...

Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in combination with Tevimbra and chemotherapy outperformed trastuzumab plus chemotherapy, and the triple combination achieved statistically significant overall survival benefit. The GEA indication repres...

Zymeworks Inc. (ZYME) surged after positive Phase 3 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma, expanding its FDA-approved indications. ZYME's partnership-driven model, strong cash position, and milestone revenues limit capital risk and provide a projected runway into 2H27. The positive Ziihera data supports regulatory submission in 2026, with key catalysts ...

Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday after the duo unveiled positive test results for a gastric cancer drug.